During the development of atherosclerotic lesions in humans or after hypercholesterolemia or deendothelialization in experimental animals, vascular smooth muscle cells (SMCs) proliferate and migrate from the media into the intima. SMCs implicated in this process show a remodeling of morphological and cytoskeletal features, which consists of a loss of microfilament bundles and a switch of actin isoform expression from α-smooth muscle to β-cytoplasmic predominance. Similar features are observed in SMCs of fetal animals, and when SMCs are placed in culture. SMCs show changes of proliferative activity and differentiation upon the stimulation with factors released from platelets, endothelial cells, T lymphocytes and macrophages, such as platelet-derived growth factor, fibroblast growth factor or γ-interferon. Extracellular matrix components such as heparin can also modulate SMC phenotypic changes. Studies on cell-cell interaction mechanisms mediated by these substances could help in the understanding of atherosclerotic plaque formation and in the planification of strategies for the prevention of this disease.

Keywords:
Cytoskeleton, Actin isoforms, Vimentin, Desmin, Endothelial injury
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.